Stephane Bancel - 28 Feb 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Executive Officer, Director
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
28 Feb 2023
Net transactions value
$0
Form type
4
Filing time
02 Mar 2023, 16:23:46 UTC
Previous filing
24 Feb 2023
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MRNA Common Stock 5,411,946 28 Feb 2023 Direct
holding MRNA Common Stock 9,050,372 28 Feb 2023 See Footnote F1
holding MRNA Common Stock 6,564,880 28 Feb 2023 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +128,830 $0.000000 128,830 28 Feb 2023 Common Stock 128,830 $138.81 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F2 These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F3 25% of this option will vest and become exercisable on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.